Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product sales	$ 9,838	$ 7,795
Product royalty revenues	440	1,661
Research and development reimbursements		22
Contract revenue	1,003	20,000
Total revenues	11,281	29,478
Cost of sales	3,415	5,645
Expenses:
Research and development	2,484	2,671
Selling, general and administrative	13,505	13,259
Total expenses	15,989	15,930
(Loss) income from operations	(8,123)	7,903
Interest expense, net	(2,505)	(2,886)
Bargain purchase gain		27,336
Other expense, net	(7)
(Loss) income before income taxes	(10,635)	32,353
Income tax (expense) benefit	(74)	15,972
Net (loss) income attributable to common stockholders	$ (10,709)	$ 48,325
Basic:
Weighted average common stock shares outstanding	58,062,997	54,519,574
Basic (loss) earnings per share	$ (0.18)	$ 0.89
Diluted:
Diluted weighted average common stock shares outstanding	58,062,997	55,431,628
Diluted (loss) earnings per share	$ (0.18)	$ 0.87